164 related articles for article (PubMed ID: 31047391)
1. Association between Industry Payments and Anti-vascular Endothelial Growth Factor Use in Medicare Beneficiaries.
Mahr MA; Hodge DO; Erie JC
Ophthalmol Retina; 2017; 1(1):19-24. PubMed ID: 31047391
[TBL] [Abstract][Full Text] [Related]
2. Physician-Industry Interactions and Anti-Vascular Endothelial Growth Factor Use Among US Ophthalmologists.
Taylor SC; Huecker JB; Gordon MO; Vollman DE; Apte RS
JAMA Ophthalmol; 2016 Aug; 134(8):897-903. PubMed ID: 27356110
[TBL] [Abstract][Full Text] [Related]
3. High Variation of Intravitreal Injection Rates and Medicare Anti-Vascular Endothelial Growth Factor Payments per Injection in the United States.
Erie JC; Barkmeier AJ; Hodge DO; Mahr MA
Ophthalmology; 2016 Jun; 123(6):1257-62. PubMed ID: 26976701
[TBL] [Abstract][Full Text] [Related]
4. Open Payments Database: Anti-Vascular Endothelial Growth Factor Agent Payments to Ophthalmologists.
Singh N; Chang JS; Rachitskaya AV
Am J Ophthalmol; 2017 Jan; 173():91-97. PubMed ID: 27697472
[TBL] [Abstract][Full Text] [Related]
5. Analysis of Anti-Vascular Endothelial Growth Factor Injection Claims Data in US Medicare Part B Beneficiaries From 2012 to 2015.
Berkowitz ST; Sternberg P; Feng X; Chen Q; Patel S
JAMA Ophthalmol; 2019 Aug; 137(8):921-928. PubMed ID: 31219520
[TBL] [Abstract][Full Text] [Related]
6. Physician Utilization Patterns for VEGF-Inhibitor Drugs in the 2012 United States Medicare Population: Bevacizumab, Ranibizumab, and Aflibercept.
Baisiwala S; Bundorf MK; Pershing S
Ophthalmic Surg Lasers Imaging Retina; 2016 Jun; 47(6):555-62. PubMed ID: 27327285
[TBL] [Abstract][Full Text] [Related]
7. Medicare Part B Spending on Macular Degeneration Treatments Associated With Manufacturer Payments to Ophthalmologists.
Dickson SR; James KE
JAMA Health Forum; 2023 Sep; 4(9):e232951. PubMed ID: 37682553
[TBL] [Abstract][Full Text] [Related]
8. Racial Differences in Age-Related Macular Degeneration and Associated Anti-Vascular Endothelial Growth Factor Intravitreal Injections among Medicare Beneficiaries.
Mahr MA; Hodge DO; Erie JC
Ophthalmol Retina; 2018 Dec; 2(12):1188-1195. PubMed ID: 31047189
[TBL] [Abstract][Full Text] [Related]
9. A 5-Year Analysis of Physician-Industry Interactions, Physician Gender, and Anti-VEGF Use in US Ophthalmologists.
Watane A; Kalavar M; Patel M; Yannuzzi N; Vanner EA; Kuriyan AE; Sridhar J
Semin Ophthalmol; 2021 Nov; 36(8):804-811. PubMed ID: 34024227
[No Abstract] [Full Text] [Related]
10. Medicare Spending on Anti-Vascular Endothelial Growth Factor Medications.
Patel S
Ophthalmol Retina; 2018 Aug; 2(8):785-791. PubMed ID: 31047530
[TBL] [Abstract][Full Text] [Related]
11. An Analysis of Medicare Reimbursement to Ophthalmologists: Years 2012 to 2013.
Han E; Baisiwala S; Jain A; Bundorf MK; Pershing S
Am J Ophthalmol; 2017 Oct; 182():133-140. PubMed ID: 28784553
[TBL] [Abstract][Full Text] [Related]
12. Pharmacotherapy for neovascular age-related macular degeneration: an analysis of the 100% 2008 medicare fee-for-service part B claims file.
Brechner RJ; Rosenfeld PJ; Babish JD; Caplan S
Am J Ophthalmol; 2011 May; 151(5):887-895.e1. PubMed ID: 21310390
[TBL] [Abstract][Full Text] [Related]
13. Trends in Anti-VEGF Injection Medicare Part B Claims among Male and Female Ophthalmologists from 2012-2016.
Pradeep T; Melachuri S; Arun S; Ravipati A; Wang S; Zhang M; Errera MH; Fu R
Semin Ophthalmol; 2021 Nov; 36(8):628-632. PubMed ID: 33678125
[No Abstract] [Full Text] [Related]
14. Trends in Anti-Vascular Endothelial Growth Factor Original Medicare Part B Claims in the United States, 2014-2019.
Desai S; Sekimitsu S; Rossin EJ; Zebardast N
Ophthalmic Epidemiol; 2024 Feb; ():1-10. PubMed ID: 38315793
[TBL] [Abstract][Full Text] [Related]
15. Estimating Medicare and Patient Savings From the Use of Bevacizumab for the Treatment of Exudative Age-related Macular Degeneration.
Rosenfeld PJ; Windsor MA; Feuer WJ; Sun SJJ; Frick KD; Swanson EA; Huang D
Am J Ophthalmol; 2018 Jul; 191():135-139. PubMed ID: 29655642
[TBL] [Abstract][Full Text] [Related]
16. Severe Ocular Inflammation Following Ranibizumab or Aflibercept Injections for Age-Related Macular Degeneration: A Retrospective Claims Database Analysis.
Souied EH; Dugel PU; Ferreira A; Hashmonay R; Lu J; Kelly SP
Ophthalmic Epidemiol; 2016; 23(2):71-9. PubMed ID: 26855278
[TBL] [Abstract][Full Text] [Related]
17. TRENDS IN INTRAVITREAL CORTICOSTEROID AGENT USE BY US OPHTHALMOLOGISTS IN MEDICARE BENEFICIARIES AND ASSOCIATION WITH PHYSICIAN-INDUSTRY INTERACTIONS.
Watane A; Kalavar M; Yannuzzi NA; Kuriyan AE; Sridhar J
Retina; 2021 Aug; 41(8):1754-1761. PubMed ID: 33315816
[TBL] [Abstract][Full Text] [Related]
18. Joint Management of Cataract Surgery by Ophthalmologists and Optometrists.
Erie JC; Hodge DO; Mahr MA
Ophthalmology; 2016 Mar; 123(3):505-13. PubMed ID: 26681394
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal Anti-Vascular Endothelial Growth Factor Cost Savings Achievable with Increased Bevacizumab Reimbursement and Use.
Glasser DB; Parikh R; Lum F; Williams GA
Ophthalmology; 2020 Dec; 127(12):1688-1692. PubMed ID: 32544559
[TBL] [Abstract][Full Text] [Related]
20. A comparison of responses to intravitreal bevacizumab, ranibizumab, or aflibercept injections for neovascular age-related macular degeneration.
Park DH; Sun HJ; Lee SJ
Int Ophthalmol; 2017 Oct; 37(5):1205-1214. PubMed ID: 27826933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
